Improvement of Iron Overload Parameters in Patients with Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Data from the Phase 3b Long-Term Rollover Study Following the BELIEVE Trial
John B. Porter(Royal London Hospital), Alì Taher(American University of Beirut Medical Center), Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Kevin H.M. Kuo(University Health Network), Marta Reverte(Bristol-Myers Squibb (Switzerland)), Jennie Zhang(Bristol-Myers Squibb (United States)), Shweta Sharma(University of Minnesota), Loyse Felber Medlin(Bristol-Myers Squibb (Switzerland)), Kefeng Wang(Bristol-Myers Squibb (United States)), Maria Dimopoulou(National and Kapodistrian University of Athens)
Cited by 1
Related Papers
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Thalassaemia
|The Lancet|2017|763
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia
|British Journal of Haematology|2000|292